Growth funding AI Optics recently secured a significant $14.7M funding round, signaling investor confidence and potential budget expansion for product development, field trials, and go-to-market activities in AI-powered retinal screening.

AI retinal focus The company is actively developing AI-based retinal screening software with plans for an end-to-end solution to detect diabetic retinopathy, glaucoma, and macular degeneration, presenting opportunities for partnerships with healthcare providers and diagnostic distributors.

Early-stage footprint With a small team size (11-50 employees) and current revenue in the low-to-mid millions, there is both agility and capacity to scale, making a compelling case for enterprise collaborations, pilot programs, and channel partnerships.

Digital health synergy Operating in medical equipment and digital health, AI Optics sits at the intersection of medical devices and AI software, enabling cross-sell opportunities with hospital systems, imaging centers, and diagnostic platforms seeking AI-assisted screening.

Geographic leverage Based in New York, NY, the company may be well-positioned to engage with US-based ophthalmology networks, healthcare accelerators, and commercial distributors seeking regional AI vision screening solutions.